ILE Isolagen

Dr. Marie Lindner Joins Isolagen, Inc. Former Vice President of Medical Market Strategy at Elan and Rhone-Poulenc Rorer Gencell Executive to Head Medical and Business Affairs EXTON, Pa., June 21 /PRNewswire-FirstCall/ -- Isolagen, Inc. (AMEX:ILE) is pleased to announce that Dr. Marie Lindner has joined the Company to serve as Senior Vice President of Medical and Business Affairs to oversee the Company's clinical studies and business development opportunities. Following an esteemed academic and medical career, Dr. Lindner spent from 1991-1998 at Rhone-Poulenc Rorer (RPR) (now Sanofi-Aventis) where she held a number of executive positions of escalating responsibility from Assistant Director of Clinical Development to Executive Director, Business Development and Licensing. During her time at RPR, Dr. Lindner spent four years at Gencell, RPR's gene and cell therapy division. Dr. Lindner then joined SmithKline Beecham (now Glaxo SmithKline) where she was Global Director of Business Development. Later, she joined Elan, where she was Vice President of Medical Market Strategy in the Drug Delivery division. Dr. Lindner's most recent position was Vice President of Strategic Business Development at BTG International, where she was responsible for acquisitions, development and licensing of medical devices and other life science products, including a wound debridement product. "We are very pleased to have someone with the breadth and depth of business and technical experience in the life sciences area to drive these critical missions of the Company. Dr. Lindner's experience in the development and licensing of medical devices and life science products is especially relevant as the Company goes forward with its clinical studies and ACE. She is a welcome addition to senior management of the Company," stated Frank DeLape, Chairman and acting CEO. Dr. Lindner received her medical degree from the Chicago Medical School (Rosalind Franklin University) and a Bachelor's Degree in Biology from Washington University. Dr. Lindner has also held a number of faculty positions at the University of Pennsylvania School of Medicine and The Children's Hospital of Philadelphia. "It is rare to find a candidate with the insight and experience to recognize and cultivate strategic business opportunities and the academic and technical knowledge to see a project through, but we believe we have found such a candidate in Dr. Lindner," stated Susan Ciallella, Executive Vice President. "We look forward to working with her to develop opportunities for the Company." Dr. Lindner is acting as a consultant until July 1st, when she will join the Company full-time in Exton to fill the newly created business development role and handle the responsibilities of Dr. Clift whose contract expired in May and was not renewed by the Company. About Isolagen, Inc. Isolagen specializes in the development and commercialization of autologous cellular therapies for soft and hard tissue regeneration. The company's product candidates are based on its proprietary Isolagen Process. Based on the accumulated experience of the company through its retrospective study, clinical trials and treatment of patients in the United Kingdom, the company believes that the Isolagen Process utilizes the patient's own cells to create safe and effective therapies to treat the underlying cause of the patient's condition. Autologous cellular therapy is the process whereby a patient's own cells are extracted, allowed to multiply and then injected into the patient. Isolagen's product candidates are designed to be minimally invasive and non-surgical. Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and actual results may differ materially from the forward-looking statements. Isolagen, Inc. does not undertake to update any such forward- looking statements or to publicly announce developments or events relating to the matters described herein. For additional information, please visit: http://www.isolagen.com/ . DATASOURCE: Isolagen, Inc. CONTACT: Martin Schmieg, Chief Financial Officer of Isolagen, Inc., +1-484-875-3099; or investor relations, Kate McNeil or John Nesbett, +1-212-825-3210, for Isolagen, Inc. Web site: http://www.isolagen.com/

Copyright